Stocktoria
Daiichi Sankyo Company, Limited 4568.T
JP · Tokyo Stock Exchange · XTKS · stock · Healthcare · website
Daiichi Sankyo Company, Limited financials (annual, from 10-K)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ¥2.12T | ¥1.89T | ¥1.60T | ¥1.28T |
| Gross profit | ¥1.45T | ¥1.47T | ¥1.19T | ¥915.0B |
| R&D expense | ¥466.0B | ¥436.0B | ¥365.2B | ¥341.6B |
| SG&A expense | ¥780.7B | ¥731.2B | ¥637.0B | ¥471.2B |
| Operating income | ¥229.1B | ¥331.9B | ¥211.6B | ¥120.6B |
| Interest expense | ¥8.0B | ¥11.9B | ¥6.0B | ¥8.5B |
| Income tax | ¥3.6B | ¥59.9B | ¥36.2B | ¥17.7B |
| Net income | ¥259.9B | ¥295.8B | ¥200.7B | ¥109.2B |
| EPS (diluted) | ¥140.37 | ¥155.87 | ¥104.62 | ¥56.91 |
| Operating cash flow | ¥77.7B | ¥53.8B | ¥599.3B | ¥114.5B |
| Free cash flow | -¥71.3B | -¥134.0B | ¥476.5B | ¥47.1B |
| Cash & equivalents | ¥449.8B | ¥639.8B | ¥647.2B | ¥441.9B |
| Inventory | ¥692.4B | ¥514.9B | ¥438.1B | ¥301.6B |
| Total assets | ¥4.01T | ¥3.46T | ¥3.46T | ¥2.51T |
| Total liabilities | ¥2.34T | ¥1.83T | ¥1.77T | ¥1.06T |
| Shareholders' equity | ¥1.66T | ¥1.62T | ¥1.69T | ¥1.45T |
Growth · year-over-year · Revenue CAGR 18.4%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +12.6% | +17.8% | +25.3% | — |
| Net income growth | -12.1% | +47.3% | +83.8% | — |
| EPS growth | -9.9% | +49.0% | +83.8% | — |
| Free cash flow growth | — | -128.1% | +910.6% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · JP · as of 2026-03-31. Figures in JPY; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.